TREM2 and Alzheimer disease: While the early use of mTORC inhibitors like rapamycin have decreased AD disease hallmarks, these inhibitors exacerbated damage in later disease stages, potentially due to the inhibition of mTORC1 interacting with TREM2, which improves amyloid plaque clearance (Razani et al., 2021; Shi et al., 2022).